

Contents lists available at [ScienceDirect](#)

Lung Cancer

journal homepage: www.elsevier.com/locate/lungcan

Corrigendum

Corrigendum to “Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials” [Lung Cancer 120 (June) (2018) 137–141]



Hossein Maymani^{a,d}, Kenneth Hess^b, Roman Groisberg^{a,d}, David S. Hong^a, Aung Naing^a, Sarina Piha-Paul^a, Filip Janku^a, Siqing Fu^a, Apostolia M. Tsimberidou^a, Shubham Pant^a, Daniel Karp^a, Shuang Liu^a, Ming Sun^a, John Heymach^c, George Simon^c, Funda Meric-Bernstam^a, Vivek Subbiah^{a,*}

^a Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA

^b Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

^c Department of Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

^d Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

The authors regret the Cancer Prevention Research Institute of Texas Grant RP110584 was incorrectly noted; it should be RP150535.

This work was supported in part by Cancer Prevention Research Institute of Texas Grant RP110584 and National Center for Advancing

Translational Sciences Grant UL1 TR000371 (Center for Clinical and Translational Sciences).

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.lungcan.2018.03.020>

* Corresponding author at: Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA.

E-mail address: vsubbiah@mdanderson.org (V. Subbiah).

<https://doi.org/10.1016/j.lungcan.2019.08.017>